In a novel intervention developed by Nancy Zucker, PhD, children with functional abdominal pain are introduced to a fun and relatable cast of characters, including Georgia the Gut Growler, Harold the Hunger Pain, and Thirsty Theo, to name just a few. She and co-authors Katharine Loeb, PhD, and Marty Gagliano, MD, recently published a book to guide primary care clinicians on delivering this treatment protocol.
NeurAxis Inc. proves that a smallcap biotech can deliver best-in-market care. That s more than great news for NRXS from a revenue perspective and for its patients from a treatment point of view. It.
Having just 1.21 million outstanding shares typically presents exceptionally well to a growth stock investor. But while it can fuel appreciable gains quickly, it can also cause downward pressure..
NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. The publication investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim. Also Read: EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy
NeurAxis is doing something other companies can t or won t do: provide a drug-free way to treat debilitating pediatric conditions, including Irritable Bowel Syndrome and Functional Abdominal Pain ..